Royalty Pharma plc Files 8-K on Financials
Ticker: RPRX · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Royalty Pharma dropped an 8-K, check it for financial updates.
AI Summary
On August 6, 2025, Royalty Pharma plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Royalty Pharma plc is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report detailing financial condition and results of operations, with no immediate indication of significant new risks.
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- August 6, 2025 (date) — Date of Report
- 110 East 59th Street (location) — Business Address
- New York, New York (location) — Business Address City/State
- 10022 (location) — Business Address Zip Code
FAQ
What is the primary purpose of this 8-K filing by Royalty Pharma plc?
The primary purpose of this 8-K filing is to report on Royalty Pharma plc's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on August 6, 2025.
What is the principal executive office address for Royalty Pharma plc?
The principal executive office address for Royalty Pharma plc is 110 East 59th Street, New York, New York 10022.
What is Royalty Pharma plc's telephone number?
Royalty Pharma plc's telephone number, including area code, is (212) 883-0200.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Royalty Pharma plc (RPRX).